Chronic%20lymphocytic%20leukemia Signs and Symptoms

Signs and Symptoms

Introduction

The most common form of adult leukemia in the Western world but less common in Asians

Definition

A chronic lymphoproliferative disorder characterized by progressive accumulation of monoclonal B-cell lymphocytes found in the blood and bone marrow

Pathophysiology

Commonly associated genetic aberrations include:
- Good prognosis: Deletions of chromosome 13q
- Poor prognosis: 17p, 11q chromosomal deletion, trisomy 12, TP53, NOTCH1, SF3B1, RPS15 gene mutations, ATM mutations with or without BIRC3 deletion, CD49d, CD38 expression, ZAP-70 expression

Signs and Symptoms

Enlarged lymph nodes
Systemic symptoms: Tiredness, fever, drenching night sweats, unintentional weight loss (≥10% in previous 6 months)
Symptoms of anemia or infection

Risk Factors

Chemical exposure
Family history: 1st-degree relatives (6- to 9-fold increased risk)
Race: Higher incidence in Caucasians compared to African Americans and Asians
Gender: Increased incidence in men compared to women

Management of MDROs in the ICU and the role of newer antimicrobial agents

Prof. David Paterson, 30 Mar 2021

Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.

Immunotherapy sparks hope for paediatric ALL

Audrey Abella, 14 Oct 2020

Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Product Highlight - Cabometyx

29 Sep 2021

Cabozantinib 60 mg, 40 mg and 20 mg tab